Safinamide is used as an add-on treatment for Parkinson’s disease, particularly in patients experiencing motor fluctuations despite optimized therapy with levodopa and other medications. It functions as a selective and reversible inhibitor of monoamine oxidase B (MAO-B), which helps increase dopamine levels in the brain, thereby improving motor control. Additionally, safinamide exhibits glutamate-release inhibition, which may contribute to neuroprotective effects and help manage symptoms like stiffness, tremors, and slowness of movement. Its dual mechanism of action helps prolong the duration of motor response and reduce off-time in patients with mid-to-late stage Parkinson’s disease. It is taken orally and offers a favorable safety profile with low risk of dietary interactions compared to non-selective MAO inhibitors.